Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
Date:5/7/2013

ingent consideration, non-current

-34,800Deferred tax liability, net, non-current

169,176178,393Other non-current liabilities

9,8176,621Total shareholders' equity

1,161,9001,121,292Total liabilities and shareholders' equity

$ 2,009,690$ 1,966,493JAZZ PHARMACEUTICALS PLCRECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES(In thousands, except per share amounts)(Unaudited)Three Months EndedMarch 31,20132012GAAP income from continuing operations

$
43,425$
30,235 Intangible asset amortization

19,55510,732 Share-based compensation expense

8,7573,281 Acquisition accounting inventory fair value step-up

1,5451,308 Transaction and integration costs

1,0226,095 Restructuring charges

949- Change in fair value of contingent consideration

4,500- Upfront license fees

4,000- Depreciation

575- Other non-cash expense 

1,22942 Income tax adjustments

(1,132)-Adjusted net income

$
84,425$
51,693GAAP income from continuing operations per diluted share

$
.71$
.52Adjusted net income per diluted share

$
.37$
.89Shares used in computing GAAP income from continuing operations and adjusted net income per diluted share amounts

61,51158,084  JAZZ PHARMACEUTICALS PLC  RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED INFORMATION  CERTAIN LINE  ITEMS AND OTHER INFORMATION  (In thousands, except per share amounts and percentages)  (Unaudited) Three Months EndedMarch 31, 2013March 31, 2012GAAPAdjustmentNon-GAAPGAAPAdjustmentNon-GAAPTotal revenues

$
96,237$
-$
96,237$
2,530$
-$
2,530Cost of product sales

27,220(2,296)

(a)

24,9247,744(1,669)

(i)

6,075Selling, general and administrative


'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Alexza Pharmaceuticals to Present at Antiepileptic Drug and Device Trials (AED) XII Conference Highlighting Advances in the Treatment of Epilepsy
3. Kinex Pharmaceuticals and Zenith Technology Corporation announce the execution of a collaborative licensing agreement
4. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
5. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
6. Valeant Pharmaceuticals Provides Efinconazole Update
7. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
8. Cumberland Pharmaceuticals Reports First Quarter Financial Results
9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
10. Webcast Alert: Isis Pharmaceuticals First Quarter 2013 Financial Results Conference Call
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)...   West Pharmaceutical Services, Inc. (NYSE: ... for injectable drug administration, announced today it plans to ... site in Waterford, Ireland . The ... cartridges and other high-value packaging components, in order to ... operational, this new site could bring approximately 150 new ...
(Date:10/1/2014)... , Oct. 1, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... into a definitive distribution agreement with Patterson Veterinary Supply. ... promote the full line of Abaxis veterinary products throughout ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, Inc. ... patented and proprietary technology used to develop and ... bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today ... from Abengoa Bioenergy for commercial scale production of ... into ethanol, developed under Abengoa,s license agreement with ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... a developer of Healthcare Technology Networks ("HTN") designed to ... today announces the launch of its proprietary Opioid Management ... United States Bone & Joint Decade , ... suffering from musculoskeletal disease filled 1.6 billion prescriptions. While ...
... SPRING, Md., April 6, 2012 Sunpeaks Ventures, ... "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution ... has entered into a sponsorship agreement ("Agreement") with a ... Clotamin, including advertising, media, and promotional elements. The Agreement ...
Cached Medicine Technology:Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 2Sunpeaks Ventures Inks Sponsorship and Marketing Agreement with Major Sports Team, Clotamin To Be Sold at Walgreens Locations Throughout Oregon and Southern Washington 3
(Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, Oct. ... the roses -- literally -- may face an increased risk of ... a study of over 3,000 older Americans, researchers found those who ... were more than three times as likely to die in the ... In fact, anosmia -- the inability to distinguish odors -- ...
(Date:10/2/2014)... at The University of Nottingham could lead to the ... A drug resulting from the research, published in the ... hope to sufferers of chronic pain conditions such as ... currently available. , The work, led by Dr Lucy ... collaboration with David Bates, Professor of Oncology in the ...
(Date:10/1/2014)... shown that more than 80 per cent of bowel ... study found that medicines called ,JAK inhibitors, halted tumour ... is present in more than 80 per cent of ... are in clinical trials, for diseases including rheumatoid arthritis, ... is the second-most common cancer in Australia with nearly ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
(Date:10/1/2014)... the adage that encourages people to keep their "eyes ... comes to exercise. When walking, staying focused on a ... appear shorter and help people walk there faster, psychology ... to walking while looking around the environment naturally, offers ... , "People are less interested in exercise if physical ...
Breaking Medicine News(10 mins):Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Medical discovery first step on path to new painkillers 2Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... novel study found that the use of Herceptin in advanced ... toxicity − nearly 28 percent of patients treated with ... lining is that much of the damage to the heart ... published online August 14 in the Journal of Clinical Oncology, ...
... OHSU Tinnitus Clinic and the School of Dentistry is ... their relationship with hearing loss//. Apparently the relationship has ... of the study leaders, said"Over the years, we have ... convinced that long-term exposure to sound from high-speed hand ...
... The three-hour open-heart surgery was performed on a 17 yr ... ,An eight-member team led by cardio thoracic surgeon ... suffering from an arterial septal, congenital defect on the 4th ... of TMCH said that the patient, S.Velumurugan's condition was stable ...
... from the US have shown that yellow plant pigments ... macular degeneration (AMD). ,The study conducted by the ... published in the Journal of Ophthalmology, states that carrots ... but brightly coloured yellow and green vegetables do have ...
... Most women who undergo surgery following an early pregnancy ... under general ,anesthesia//. However a new study has raised ... ,Early pregnancy failure - or EPF - occurs in ... with surgery typically haven't been performed in ,an office-based ...
... of a fourth drug to the usual three-drug HIV treatment ... did not reduce the HIV load// or the drug resistance, ... 16 issue of JAMA, a theme issue on HIV/AIDS. ... of Cornell University, New York, presented the findings of the ...
Cached Medicine News:Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 2Health News:Herceptin Use May Enhance Cardiac Toxicity, Study 3Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 2Health News:Is There a Connection between Hearing loss and High-speed Dental Tools? 3Health News:Yellow Fruits And Vegetables Help In Fight Against Loss Of Eyesight 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 2Health News:Women Prefer Office Procedure during treatment of Early Pregnancy 3Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
Medicine Products: